[{"data":1,"prerenderedAt":170},["ShallowReactive",2],{"drug-ertugliflozin":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":43,"contraindications":69,"warnings":79,"renal":87,"monitoring":95,"interactions":96,"review":97,"examples":100,"atc":106,"iran":108,"usApproval":115,"links":121,"populations":135},"ertugliflozin",1,{"fa":7,"en":8},"ارتوگلیفلوزین","Ertugliflozin","alimentary-metabolism",{"fa":11,"en":12},"مهارکننده SGLT2","SGLT2 inhibitor",[14],{"name":15,"market":16},"Steglatro","US",[18,19,7],"steglatro","استگلاترو",[21,35],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":30,"refs":31},"tab-5","tablet","oral","5 mg tablet",{"amount":27,"unit":28,"perUnit":23,"scored":29},5,"mg",false,[16],[32],{"source":33,"section":34},"fda-steglatro","3",{"id":36,"form":23,"route":24,"label":37,"concentration":38,"markets":40,"refs":41},"tab-15","15 mg tablet",{"amount":39,"unit":28,"perUnit":23,"scored":29},15,[16],[42],{"source":33,"section":34},[44],{"id":45,"disease":46,"label":47,"population":50,"type":54,"unit":28,"dose":55,"refs":56,"notes":59},"t2dm","type-2-diabetes",{"fa":48,"en":49},"دیابت نوع ۲ بزرگسال — ۵ mg صبح؛ تا ۱۵ mg یک بار","Type 2 diabetes, adults — 5 mg in the morning; up to 15 mg once daily",{"minAge":51},{"value":52,"unit":53},18,"year","fixed",{"perDose":27,"perDoseMax":39,"dosesPerDay":5},[57],{"source":33,"section":58},"2.2",[60],{"text":61,"refs":64},{"fa":62,"en":63},"پیش از شروع کمبود حجم اصلاح شود. دست‌کم ۴ روز پیش از جراحی قطع.","Correct volume depletion first. Withhold ≥4 days before surgery.",[65,67],{"source":33,"section":66},"2.1",{"source":33,"section":68},"2.3",[70],{"id":71,"severity":72,"text":73,"refs":76},"hyper","block",{"fa":74,"en":75},"حساسیت به ارتوگلیفلوزین.","Hypersensitivity to ertugliflozin.",[77],{"source":33,"section":78},"4",[80],{"text":81,"refs":84},{"fa":82,"en":83},"کتواسیدوز (حتی با قند نه‌چندان بالا)؛ قطع عضو تحتانی؛ کاهش حجم؛ عفونت ادراری-تناسلی و گانگرن فورنیه؛ هیپوگلیسمی با انسولین یا سولفونیل‌اوره.","Ketoacidosis (even with modest glucose); lower-limb amputation; volume depletion; genitourinary infections incl. urosepsis; hypoglycaemia with insulin or sulfonylureas.",[85],{"source":33,"section":86},"5",[88],{"egfrBelow":89,"severity":72,"text":90,"refs":93},45,{"fa":91,"en":92},"eGFR زیر ۴۵: توصیه نمی‌شود.","eGFR \u003C45: not recommended.",[94],{"source":33,"section":58},[],[],{"status":98,"reviewer":99,"date":99},"unverified",null,[101],{"regimen":45,"formulation":22,"input":102,"expect":105},{"ageYears":103,"weightKg":104},55,80,{"perDose":27,"tabletsPerDoseRounded":5,"upperPerDose":39},[107],"A10BK04",{"status":109,"refs":110},"not-found",[111],{"source":112,"section":113,"url":114},"darooyab-generic","search","https:\u002F\u002Fwww.darooyab.ir\u002FSearch?q=Ertugliflozin",{"kind":116,"refs":117,"id":120},"NDA",[118],{"source":33,"section":119},"SPL approval \u002F marketing category","NDA209803",[122,125,129,132],{"kind":123,"url":124,"label":120},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=209803",{"kind":126,"url":127,"label":128},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=e6f3e718-bb99-48f1-ab94-b9f0af05fed6","FDA Steglatro",{"kind":130,"url":131,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa618011.html",{"kind":133,"url":134,"label":107},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=A10BK04",{"pregnancy":136,"lactation":145,"pediatric":153,"geriatric":162},{"level":137,"text":138,"quote":141,"refs":142},"caution",{"fa":139,"en":140},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary Based on animal data showing adverse renal effects, STEGLATRO is not recommended during the second and third trimesters of pregnancy.",[143],{"source":33,"section":144},"8.1",{"level":137,"text":146,"quote":149,"refs":150},{"fa":147,"en":148},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary There is no information regarding the presence of STEGLATRO in human milk, the effects on the breastfed infant, or the effects on milk production.",[151],{"source":33,"section":152},"8.2",{"level":154,"text":155,"quote":158,"refs":159},"not-established",{"fa":156,"en":157},"برچسب: ایمنی و اثربخشی در کودکان ثابت نشده است.","Label: safety and effectiveness in children have not been established.","Safety and effectiveness of STEGLATRO in pediatric patients under 18 years of age have not been established.",[160],{"source":33,"section":161},"8.4",{"level":137,"text":163,"quote":166,"refs":167},{"fa":164,"en":165},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","… %, and 2.6% of patients treated with comparator, STEGLATRO 5 mg, and STEGLATRO 15 mg, respectively [see Warnings and Precautions (5.3) and Adverse Reactions (6.1) ] .",[168],{"source":33,"section":169},"8.5",1792191542364]